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A Ab bs st tr ra ac ct t
O Ob bj je ec ct ti iv ve es s: :   To conduct a pilot population-based study within a general practice catchment area to determine
whether the incidence of breast cancer was increased in the Ashkenazi population.
D De es si ig gn n: :   Population-based cohort study.
S Se et tt ti in ng g: : A single general practice catchment area in North London.
P Pa ar rt ti ic ci ip pa an nt ts s: :   1947 women over the age of 16 who responded to a questionnaire about ethnicity and breast cancer.
M Ma ai in n   o ou ut tc co om me e   m me ea as su ur re es s: :   Incidence of breast cancer, ethnicity.
R Re es su ul lt ts s: :   This study showed a 1.5-fold (95% CI 0.93-2.39) increase in breast cancer risk in the Ashkenazim
compared with the non-Ashkenazi white population. The increased incidence was for both premenopausal and
postmenopausal breast cancer (expected incidence pre:post is 1:4 whereas in the Ashkenazim it was 1:1; 51
and 52% of cases respectively). This increase was not shown in the Sephardim. Asians had a reduction in incidence
(OR=0.44; 95% CI 0.10-1.89). Results were adjusted for other risk factors for breast cancer.
C Co on nc cl lu us si io on ns s: :   This study showed a 1.5-fold increase in breast cancer rates in Ashkenazim compared with the non-
Jewish white population when adjusted for age (i.e. corrections were made to allow comparison of age groups)
and this is not observed in the Sephardic population. The proportion of premenopausal breast cancer was just
over double that of the general population. This is the first general practice population-based study in the UK to
address this issue and has implications for general practitioners who care for patients from the Ashkenazi community.
I In nt tr ro od du uc ct ti io on n
General practice offers the doctor the privilege of
caring for individuals and their families over many
episodes and sometimes for many years, allowing doctors
a unique insight into the impact of health and illness on
individuals’ physical and psychosocial wellbeing. This
study was undertaken in a GP practice in a multi-ethnic
catchment area in North-West London with a high
proportion of Jewish families. Within this practice thereH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(3) 158
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was an apparent cluster of breast cancer diagnoses in
young Jewish women under 45 years, a diagnosis which
had obvious medical and psychosocial consequences for
both the women themselves and their young families. This
also had a presumed extended impact upon the close-
knit Jewish community and an observed impact on the
general practice staff and palliative care teams.
An increased frequency of germline mutations in the
breast cancer predisposition genes BRCA1 and BRCA2
is known to exist within the Ashkenazi Jewish population
[1-3]. Several authors have investigated whether there
is an increased breast cancer incidence in this
population, with varying results. Newill [4] noted an
increased incidence of breast cancer within the New York
Jewish population in the late 1950s. Egan et al. [5]
found that, while the relative risk of breast cancer was
not significantly different for Ashkenazi women in general,
there was a slight elevation in relative risk for younger
women. There was a greater increase in relative risk for
women with a family history of cancer than there was for
similar women of different religious background. This
was again based on a population of American women.
Feldman [6] did not find any evidence of increased breast
cancer risk for Ashkenazi women. Breast cancer
incidence is lower in Israel, which has a larger proportion
of Ashkenazi Jewish individuals, than in Northern
European countries such as the United Kingdom [7].
The local observation in general practice of a large
number of young breast cancer cases prompted MF,
in collaboration with the co-authors and Prof Modell
(see acknowledgements), to determine if this apparent
increased incidence of breast cancer in the Jewish
community was a real effect and also whether it was
uniform across different types of Jewish origin.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
The audit was set in one general practice in North
West London. The general practice serves a population
of 11 000 of whom 4772 were females over the age of
16 years. A computer search (Vision, In Practice) was
conducted to ascertain all the cases of breast cancer
within the general practice. The search used the
interrogations ’’breast cancer’’ or ’’tamoxifen treatment’’.
Sixty-six women thus identified were sent a questionnaire
to determine their age at diagnosis, menopausal status
at diagnosis, lifetime oral contraceptive (OC) and
hormone replacement therapy (HRT) use, smoking and
breast feeding history, and family history of breast,
ovarian or colorectal cancer. They were asked in detail
about their ethnicity; in particular, those who were Jewish
were further characterised as being from one of the two
diaspora, either the Sephardim (of Mediterranean origins)
or Ashkenazim (from Eastern Europe), because until
recently these two populations lived in relative isolation
from each other over a number of centuries.
The remaining women in the general practice were
sent an amended questionnaire to identify a further
cohort of breast cancer cases whose breast cancer
diagnoses predated the computerisation of the GP or
before tamoxifen was used for breast cancer treatment.
This cohort comprised women diagnosed with breast
cancer before 1990. The amended questionnaire also
provided details of breast cancer risk factors in the
unaffected female population.
The recruitment letter and questionnaire were
designed to capture information on known or suspected
risk factors for breast cancer in the whole general practice
population. An ethnicity section was included, but neither
the recruitment letter nor the questionnaire emphasised
this to avoid bias due to non-response in one group.
Odds ratios for breast cancer were estimated using
logistic regression, adjusting for age in ten-year strata.
R Re es su ul lt ts s
This study was conducted in 1999. The general
practice population catchment size was 11 000 of
whom 4772 were females over the age of 16 years.
Twelve were deemed too ill or too anxious to be sent
a questionnaire. All of these 4760 women were sent
a questionnaire and 1947 women responded (41%
response rate). 1637 of the 1947 were in the groups
listed in Table 1. The other ethnic groups were too
various for a robust analysis (the classification of other
was Afro-Caribbean, Mediterranean and other). There
were 93 breast cancer cases aged 29-90 years;
median 41.5 years. Sixty-six were identified from the
computerised records and a further 27 from the
questionnaires sent to all women over 16 years. All 93
answered the questionnaire. 39.4% of the general
practice’s women were Ashkenazi Jewish; however 51%
of the premenopausal cancers were in the Ashkenazim
and 52% of the postmenopausal cases also.
Table 1 shows that the point-estimated breast cancer
risk is 1.5-fold higher among Ashkenazi women than
non-Jewish whites, though the difference is not
significant (OR=1.49, 95% CI 0.93-2.39; p=0.10).
The increased breast cancer risk is seen in both
premenopausal and postmenopausal women (>50
years and <50 years respectively). The Sephardic
population has rates nearer to those of the white
population, though again the differences are not
significant. However, the population of the Sephardim
is small (7 questionnaires and 2 breast cancers). The
rates for Asians are just under half those of whites andH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(3) 159
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just under a third of those in the Ashkenazim. Table 2
shows the distribution of age, breastfeeding,
menopausal status, OC use and HRT use by ethnic
group (both those affected and unaffected with breast
cancer). Table 3 shows that all other groups are more
likely to breastfeed and to use hormone replacement
therapy (HRT) than whites; however, the Sephardim and
Asians have less oral contraceptive (OC) use than whites
T Ta ab bl le e   3 3. .   Risk factor distributions by ethnic group overall (not divided by diagnosis). Odds ratios for each risk factor by ethnic group, relative
to non-Jewish whites
F Fa ac ct to or r A As sh hk ke en na az zi i S Se ep ph ha ar rd di i A As si ia an n
Breastfeeding 1.42 (1.14-1.76) 2.83 (1.53-5.23) 3.13 (2.01-4.87)
Menopause 0.92 (0.61-1.40) 1.23 (0.38-3.97) 1.42 (0.67-2.99)
OC use 1.06 (0.81-1.40) 0.76 (0.38-1.51) 0.26 (0.17-0.42)
HRT use 1.74 (1.30-2.32) 2.05 (1.00-4.20) 1.84 (1.04-3.24)
T Ta ab bl le e   2 2. .   Distribution of other risk factors by ethnic group in the whole population who returned questionnaires
W Wh hi it te e    A As sh hk ke en na az zi i S Se ep ph ha ar rd di ic c A As si ia an n
N No o. .   ( (% %) ) N No o. .   ( (% %) ) N No o. .   ( (% %) ) N No o. .   ( (% %) )
A Ag ge e   a at t   q qu ue es st ti io on nn na ai ir re e   c co om mp pl le et ti io on n < <3 30 0 36 (5) 47 (6) 2 (3) 16 (12)
3 30 0- -3 39 9 97 (13) 71 (9) 9 (15) 30 (22)
4 40 0- -4 49 9 100 (13) 126 (17) 9 (15) 34 (25)
5 50 0- -5 59 9 118 (15) 188 (25) 9 (15) 28 (21)
6 60 0- -6 69 9 112 (15) 111 (15) 15 (25) 16 (12)
7 70 0- -7 79 9 131 (17) 85 (11) 3 (5) 10 (7)
8 80 0+ + 169 (22) 129 (17) 12 (20) 1 (1)
B Br re ea as st tf fe ee ed di in ng g e ev ve er r 366 (48) 417 (55) 40 (69) 84 (62)
n ne ev ve er r 400 (52) 338 (45) 18 (31) 51 (38)
M Me en no op pa au us sa al l   s st ta at tu us s p pr re e 474 (62) 416 (55) 35 (71) 46 (34)
p po os st t 293 (38) 342 (45) 24 (29) 89 (66)
O OC C   u us se e e ev ve er r 348 (45) 394 (52) 27 (46) 56 (41)
n ne ev ve er r 419 (55) 363 (48) 32 (54) 79 (59)
H HR RT T   u us se e e ev ve er r 118 (15) 173 (23) 15 (25) 24 (18)
n ne ev ve er r 649 (85) 585 (77) 44 (75) 111 (82)
T Ta ab bl le e   1 1. .   Breast cancer (BrCa) odds ratios (OR), relative to non-Jewish whites
G Gr ro ou up p B Br rC Ca a/ /T To ot ta al l O OR R   ( (9 95 5% %   C CI I) ) O OR R   ( (9 95 5% %   C CI I) )
( (a ad dj ju us st te ed d   f fo or r   a ag ge e) ) ( (a ad dj ju us st te ed d   f fo or r   a ag ge e, ,   b br re ea as st tf fe ee ed di in ng g, ,   
O OC C   a an nd d   H HR RT T) )
White 32/735 1.0 1.0
Ashkenazi 47/712 1.49 (0.93-2.39) 1.47 (0.91-2.39)
Sephardic 2/57 0.82 (0.19-3.54) 0.83 (0.19-3.64)
Asian 2/133 0.44 (0.10-1.89) 0.35 (0.08-1.52)H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(3) 160
or the Ashkenazim. Adjustments for breastfeeding, OC
and HRT use do not affect the results. The Asian
population is markedly younger than the other groups.
D Di is sc cu us ss si io on n
It is known from genetic testing studies in breast
cancer patients in New York [1] that the Ashkenazim with
breast cancer have a higher incidence of mutations in
breast-cancer-predisposition genes. This is the first
population-based study within a GP setting in the UK to
determine the breast cancer incidence in this population.
We have shown that the breast cancer rates in the
Ashkenazim are approximately 1.5-fold higher than in
non-Jewish whites when adjusted for age and that these
rates are not observed in the Sephardi population. The
Asian community in this general practice catchment
area has a lower breast cancer incidence than the non-
Jewish or white Jewish populations. The adjustment in
the analysis which we have performed to account for
confounders such as HRT use, since this is known to
increase breast cancer risk, means that other factors
are likely to be responsible.
It is known that the Ashkenazim have a higher
proportion of founder mutations in the breast cancer
predisposition genes BRCA1 and  BRCA2 [1-3];
however, previous studies have been hospital-
population-based or have specifically targeted certain
groups such as cancer patients. As the first 
GP-population-based study in the UK, this analysis
reduces the ascertainment bias as the women involved
were not self-selected. All the patients with a breast cancer
diagnosis completed the health questionnaire, whereas
only a proportion of those unaffected responded.
The increased breast cancer risk in the Ashkenazim
is seen in both premenopausal and postmenopausal
women; thus the general practitioners’ perception that
there was a higher rate of breast cancer in young
Ashkenazim was correct. The incidence in
postmenopausal Ashkenazim was similarly high. The
increase in premenopausal breast cancers has
implications for the recommended mode of screening
as mammography in this age group is less sensitive.
Although the confidence intervals include 1.00, this study
has provided pilot data which indicate that there may
be an increased breast cancer incidence in the
Ashkenazim that is not explained by a difference in
hormonal factors or family history in first-degree relatives.
This study raises some important issues. The point-
estimate increased risk observed by us is not high
enough to justify earlier mammographic screening from
the NICE guidelines [8], which suggest screening for
women whose increase in breast cancer risk is at least
1.7-fold. However, if substantiated, the findings of this
study will have implications for GPs who care for
individuals from this ethnic background as there should
be a heightened awareness of breast cancer risk in the
Ashkenazi Jewish population.
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